Distinct Effects of Tissue-Type Plasminogen Activator and SMTP-7 on Cerebrovascular Inflammation Following Thrombolytic Reperfusion | Zendy

Takuro Miyazaki | Zendy; Yuji Kimura | Zendy; Hisayuki Ohata | Zendy; Terumasa Hashimoto | Zendy; Keita Shibata | Zendy; Keiji Hasumi | Zendy; Kazuo Honda | Zendy

Open Access

Distinct Effects of Tissue-Type Plasminogen Activator and SMTP-7 on Cerebrovascular Inflammation Following Thrombolytic Reperfusion

Author(s) -

Takuro Miyazaki,

Yuji Kimura,

Hisayuki Ohata,

Terumasa Hashimoto,

Keita Shibata,

Keiji Hasumi,

Kazuo Honda

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.110.598359

Subject(s) - medicine , inflammation , tissue plasminogen activator , plasminogen activator , stroke (engine) , cardiology , fibrinolytic agent , thrombolysis , fibrinolysis , pharmacology , myocardial infarction , mechanical engineering , engineering

Thrombolysis therapy using tissue-type plasminogen activator (t-PA) is occasionally accompanied by harmful outcomes, including intracerebral hemorrhage. We have reported that Stachybotrys microspora triprenyl phenol-7 (SMTP-7), a candidate thrombolytic drug, has excellent therapeutic effect on cerebral infarction in embolic stroke model in mice; however, little is known regarding whether this agent influences cerebrovascular inflammation following thrombolytic reperfusion. The current study aimed to compare the effects of recombinant t-PA (rt-PA) and SMTP-7 on cerebrovascular inflammation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research